Tüdőrák: vizsgálatok itt: Spanyolország
275 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 17.. Ask the study team whether a trial fits you.
- 2/3. fázisTaking peopleA Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
- Where
- Barcelona, Madrid, Málaga, Sabadell, Santiago de Compostela, Valencia, Zaragoza
- Életkor
- 18 év and over
- People
- 490 worldwide
- Run by
- AbbVie
See details and how to joinNCT07155187 · EU 2025-521124-29-00 - 1. fázisTaking peopleA Study of ZW251 in Participants With Advanced Solid Tumors
- Where
- Barcelona, Logroño, Madrid, Málaga, Pamplona
- Életkor
- 18 év and over
- People
- 140 worldwide
- Run by
- Zymeworks BC Inc.
See details and how to joinNCT07164313 - 1/2. fázisTaking peopleThe Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Where
- Barcelona, Madrid, Rioja, Valencia
- Életkor
- 12 év and over
- People
- 300 worldwide
- Run by
- PMV Pharmaceuticals, Inc
See details and how to joinNCT04585750 - 3. fázisTaking peopleEffect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer
- Where
- A Coruna, Badalona, Barcelona, Córdoba, Elche, Lleida, Madrid, Málaga, Móstoles, Reus, San Cristóbal de La Laguna, Santiago de Compostela, Sevilla, Torrejón de Ardoz, Valencia, Vigo, Zaragoza
- Életkor
- 18 év and over
- People
- 120 worldwide
- Run by
- Pharmacosmos A/S
See details and how to joinNCT07473128 · EU 2025-525026-35-00 - 1. fázisTaking peopleStudy of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Where
- Badajoz, Barcelona, Madrid, Pamplona, Santander, Sevilla, Valencia
- Életkor
- 18 év and over
- People
- 1394 worldwide
- Run by
- Exelixis
See details and how to joinNCT05176483 · EU 2023-510061-10-00 - 1/2. fázisTaking peopleA Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)
- Where
- A Coruña, Barcelona, Girona, L'Hospitalet de Llobregat, Madrid, Majadahonda, Málaga, Pozuelo de Alarcón, Sevilla, Valencia, Vigo
- Életkor
- 18 év and over
- People
- 123 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06362252 · EU 2023-509629-36-00 - 1. fázisTaking peopleOpen-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- Where
- Barcelona, Lleida, Madrid, Pozuelo de Alarcón, Valencia
- Életkor
- 18 év and over
- People
- 392 worldwide
- Run by
- TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
See details and how to joinNCT06625775 · EU 2024-519445-29-00 - 2. fázisTaking peopleA Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)
- Where
- Barcelona, Logrono, Lugo, Madrid, Málaga, Valencia
- Életkor
- 18 év and over
- People
- 243 worldwide
- Run by
- Shanghai Henlius Biotech
See details and how to joinNCT06907615 · EU 2025-523803-31-00 - 1/2. fázisTaking peopleA Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
- Where
- Barcelona, L'Hospitalet de Llobregat, Pozuelo de Alarcón, Sevilla
- Életkor
- 18 év and over
- People
- 140 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07286149 · EU 2024-512248-47-00 - 3. fázisTaking peopleNeladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
- Where
- A Coruña, Badalona, Barcelona, Girona, L'Hospitalet de Llobregat, Madrid, Málaga, Sevilla
- Életkor
- 18 év and over
- People
- 450 worldwide
- Run by
- Nuvalent Inc.
See details and how to joinNCT06765109 · EU 2024-517553-26-00 - 1. fázisTaking peopleA Study of PHN-012 in Patients With Advanced Solid Tumors
- Where
- Barcelona, Madrid, Valencia
- Életkor
- 18 év and over
- People
- 165 worldwide
- Run by
- Pheon Therapeutics
See details and how to joinNCT07127874 - No phaseTaking peopleOSIREAL - Osimertinib RWE on EGFRm NSCLC in Spain
- Where
- A Coruña, Alicante, Barcelona, C Rdoba, El Palmar, Girona, Granada, Jaén, Las Palmas de Gran Canaria, León, Lleida, Madrid, Málaga, Ourense, Palma, Sabadell, Salamanca, Santa Cruz de Tenerife, Santander, Santiago de Compostela, Seville, Valencia, Valladolid, Vigo, Zaragoza
- Életkor
- 18 év and over
- People
- 500
- Run by
- AstraZeneca
See details and how to joinNCT06068049 - 3. fázisTaking peopleA Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
- Where
- Badajoz, Badalona, Barcelona, Castello De La Plana, Jaén, Lugo, Madrid, Málaga, Oviedo, Palma, Valencia, Vigo, Zaragoza
- Életkor
- 18 év and over
- People
- 830 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06868277 · EU 2024-517780-24-00 - 1. fázisTaking peopleA Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-8520 in Subjects with Advanced KRASG12C Mutant Non-Small Cell Lung Cancer - The ONKORAS-101 Study
- Where
- Barcelona, L'Hospitalet de Llobregat, Madrid, Pozuelo de Alarcón, Valencia
- Életkor
- 18 év and over
- People
- 45 worldwide
- Run by
- Theras Inc.
See details and how to join2024-512515-45-01 - 1/2. fázisTaking peopleA Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
- Where
- A Coruña, Barcelona, Madrid
- Életkor
- 12 év and over
- People
- 359 worldwide
- Run by
- Nuvalent Inc.
See details and how to joinNCT05118789 · EU 2024-511793-71-00 - 1/2. fázisTaking peopleA Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
- Where
- Barcelona, Hospitalet, Madrid, Majadahonda, Málaga, Santiago de Compostela, Seville, Valencia
- Életkor
- 18 év and over
- People
- 416 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06618287 - 3. fázisTaking peopleA Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
- Where
- Barcelona, Madrid, Majadahonda
- Életkor
- 18 év and over
- People
- 531 worldwide
- Run by
- AbbVie
See details and how to joinNCT07365241 · EU 2025-523819-11-00 - 1. fázisTaking peopleA study of Daraxonrasib (RMC-6236) in combination with pembrolizumab in participants with nonsmall cell lung cancer with certain mutations -Subprotocol B
- Where
- A Coruña, Badalona, Barcelona, Madrid, Málaga, Pamplona, Sevilla, Valencia
- Életkor
- 18 év and over
- People
- 180 worldwide
- Run by
- Revolution Medicines Inc.
See details and how to join2023-509572-42-00 - 1/2. fázisTaking peopleStudy of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Where
- Barcelona, Madrid, Pamplona, Seville, Valencia, Zaragoza
- Életkor
- 18 év and over
- People
- 534 worldwide
- Run by
- Revolution Medicines, Inc.
See details and how to joinNCT06128551 - 1. fázisFut, nem toborozA Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)
- Where
- Madrid
- Életkor
- 18 év and over
- People
- 232 worldwide
- Run by
- AbbVie
See details and how to joinNCT06858813 · EU 2024-518012-39-00 - 1. fázisNot yet taking people in SpanyolországPhase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
- Where
- Barcelona, Madrid
- Életkor
- 18 év to 100 év
- People
- 116 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07006727 · EU 2024-519111-34-00 - 1. fázisFut, nem toborozA Phase 1 Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Denikitug (GS-1811), an Afucosylated Anti-CCR8 Monoclonal Antibody, as Monotherapy and in Combination With an Anti–PD-1 Monoclonal Antibody in Adults With Advanced Solid Tumors
- Where
- Barcelona, Madrid, Pamplona, Pozuelo de Alarcón
- Életkor
- 18 év and over
- People
- 93 worldwide
- Run by
- Gilead Sciences Inc.
See details and how to joinNCT05007782 · EU 2022-501684-40-00 - 1. fázisTaking peopleEvaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Where
- Barcelona, Madrid, Piqueras, Seville
- Életkor
- 18 év and over
- People
- 540 worldwide
- Run by
- SystImmune Inc.
See details and how to joinNCT05983432 - 2. fázisTaking peopleA Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2
- Where
- Alicante, Barcelona, Majadahonda
- Életkor
- 18 év and over
- People
- 48 worldwide
- Run by
- ETOP IBCSG Partners Foundation
See details and how to joinNCT07203053 · EU 2025-522288-13-00 - 1/2. fázisNot yet taking people in SpanyolországA First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
- Where
- Barcelona, Madrid, Pamplona, Pozuelo de Alarcón
- Életkor
- 18 év and over
- People
- 265 worldwide
- Run by
- Blueprint Medicines Corporation
See details and how to joinNCT07629960